Skip to content


  • Poster presentation
  • Open Access

Analysis of the IgE epitope profile of soybean allergen Gly m 4

  • 1,
  • 2,
  • 3,
  • 3,
  • 1,
  • 4,
  • 5,
  • 6,
  • 6,
  • 7,
  • 1,
  • 1,
  • 3,
  • 1,
  • 1 and
  • 1
Clinical and Translational Allergy20144 (Suppl 2) :P42

  • Published:


  • Birch Pollen
  • Clinical Reactivity
  • Oral Food Challenge
  • Substitutional Variant
  • Epitope Residue


Individuals with birch pollinosis may show allergic reactions after consumption of soybean-containing food. This is caused by cross-reaction of IgE directed against the major birch pollen allergen Bet v 1 with its homologue Gly m 4 from soybean. Birch pollen allergic subjects without soybean allergy often present IgE binding to Gly m 4.


To identify IgE epitopes of Gly m 4 in birch pollen-allergic subjects with and without allergy to soybean.


Sera from 33 birch pollen-allergic patients with and without clinical reactivity to soy as determined by oral food challenge or convincing history of soy allergy were included in the study. Specific IgE against Bet v 1 and Gly m 4 was determined by ImmunoCAP. IgE binding of the sera to rGly m 4 and soy extract was tested in western blot analysis. To predict putative IgE epitopes, 20 IgE-binding phage-displayed peptide mimics and heptamers representing the total Gly m 4 amino acid sequence were bioinformatically mapped onto the molecular surface of Gly m 4. To verify predicted epitopes, Gly m 4 variants with substituted epitope residues were expressed in and purified from E. coli. Secondary and tertiary structures were assessed by CD and NMR spectroscopy. IgE binding of variants was analyzed by competitive immunoblotting and inhibition ELISA.


Gly m 4- and Bet v 1-specific IgE levels ranged from 0 to >100 kUA/L in sera of both patient groups. CAP values were above 3.5 kUA/L in 18 sera (86%) of patients with clinical soy allergy and in 7 sera (58%) of patients sensitized, but without clinical reactivity to soy, respectively. Intensity of IgE binding in western blot corresponded to ImmunoCAP analysis. Bioinformatic mapping resulted in four distinct epitopes on Gly m 4 surface. Several amino acid residues were chosen for generation of substitutional variants. Purified rGly m 4 variants showed a typical Bet v 1-like structure according to CD spectra and 1D-1H-NMR spectroscopy. IgE binding to several substitutional variants was reduced, indicating a multiple number of epitopes on Gly m 4 surface.


No significant differences in Gly m 4-specific IgE binding could be observed between birch pollen-allergic patients with and without clinical soy allergy in ImmunoCAP and immunoblot analysis. However residual IgE reactivity persists in substitutional rGly m 4 variants, indicating the presence of further IgE epitopes not yet identified.

Authors’ Affiliations

Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany
Australian Red Cross Blood Service, Research & Development Division, Melbourne, Australia
Department of Biopolymers, University of Bayreuth, Bayreuth, Germany
Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Allergy and Asthma Center Westend, Praxis Hanf, Ackermann & Kleine-Tebbe, Berlin, Germany
Department of Dermatology and Allergology, University of Leipzig, Leipzig, Germany
Department of Biostatistics, Paul-Ehrlich-Institut, Langen, Germany


© Husslik et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.